Biofrontera Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BFRI research report →
Price Chart
About the company
Biofrontera Inc. , a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
- CEO
- Hermann Lübbert
- IPO
- 2021
- Employees
- 89
- HQ
- Woburn, MA, US
Get TickerSpark's AI analysis on BFRI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.87M
- P/E
- -1.33
- Fwd P/E
- 1.32
- PEG
- -0.01
- P/S
- 0.16
- P/B
- -33.33
- EV/EBITDA
- -2.28
- Div Yield
- 0.00%
- Gross Margin
- 84.60%
- Op Margin
- -9.50%
- Net Margin
- -12.72%
- ROE
- -110.30%
- ROIC
- -59.58%
Latest fiscal year · YoY change
- Revenue
- $41.70M+11.8%
- Gross Profit
- $32.80M+75.5%
- Op Income
- $-9,148,000
- Net Income
- $-10,536,000+40.7%
- EPS
- $-1.04+67.7%
- OCF Growth
- -30.1%
- FCF Growth
- -29.4%
- 52W High
- $1.66
- 52W Low
- $0.53
- 50D MA
- $0.95
- 200D MA
- $1.02
- Beta
- 0.96
- RSI (14)
- 27
- Avg Volume
- 432.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Biofrontera reported 30% revenue growth and strong commercial momentum, but quarter-end cash, a stockholders’ deficit, and going-concern language remain key overhangs despite regulatory and ITC wins.· November 13, 2026
- Q3 product revenue was $9.1 million, up 29.8% year over year, driven by 23.3% Ameluz unit growth plus pricing and higher device sales.
- Gross margin improved to 74.4% from 70.7% a year ago, though Q3 margin was pressured by $300,000 of RhodoLED inventory write-downs and higher lamp costs.
- The FDA approved Ameluz for superficial basal cell carcinoma on September 9, and management plans a full launch in Q1 2027 after feedback on marketing materials.
- Customs ruled the redesigned RhodoLED XLC does not infringe the asserted DUSA patents and is not subject to the ITC exclusion order; management said remediation should be substantially complete by the end of Q2 2027.
- Liquidity remains tight: cash was $3.2 million at September 30, the company reported a $200,000 stockholders’ deficit, and management disclosed substantial doubt about its ability to continue as a going concern.
Q3 2026 product revenue was $9.1 million, up 29.8% from $7.0 million last year. Ameluz tube volume was approximately 25,100, up 23% from 20,400 in Q3 2025. Gross profit was $6.7 million and gross margin was 74.4%, versus 70.7% a year ago. Net loss was $6.4 million, or $0.42 per share, compared with a net loss of $6.6 million, or $6.02 per share last year; adjusted EBITDA was negative $5.5 million versus negative $6.0 million. For the first nine months, revenue was $31.2 million, up 26.6%, gross margin was 78.0% versus 67.7%, net loss was $11.8 million versus $16.2 million, and adjusted EBITDA was negative $9.3 million versus negative $15.5 million. Cash and cash equivalents were $3.2 million at September 30, total liabilities were $21.7 million, and the company had about $4.7 million of convertible notes maturing in November 2027. Management expects Q4 to be the strongest quarter and expects gross margin to return to around 80% absent Q3-style charges; it also expects to begin commercializing the sBCC indication in Q1 2027, and the AK supplemental NDA has a PDUFA date of August 5, 2027.
Hermann Luebbert framed the quarter as a turning point in what the company can sell and to whom. He emphasized that Ameluz now has a second U.S. indication, called the FDA approval for superficial basal cell carcinoma a first-in-the-U.S. PDT approval for skin cancer, and said the company has a third indication filed plus a lamp portfolio that is clear of the ITC exclusion order. His tone was defiant but cautious: he repeatedly noted that the company had to absorb the cost of getting through the legal and remediation issues, while stressing that the commercial base and launch infrastructure are now in place.
Fred Leffler highlighted the financial impact of the ITC matter and the underlying operating trend. He said gross margin was 74.4%, down from about 80% in the first half because of $400,000 of higher lamp/device costs and $300,000 of RhodoLED inventory write-downs, including a $200,000 write-down of XL long-term raw materials and work in process. SG&A was $12.5 million, up $2.1 million, mainly from $900,000 of higher legal fees related to the ITC matter, plus higher manufacturing/regulatory costs taken in-house and higher commissions; cash at September 30 was $3.2 million, and the company disclosed substantial doubt about its ability to continue as a going concern. He said the plan includes growing revenue, securing a working line of credit, collecting a expected $1 million milestone payment in December from the [inaudible] divestiture, and possibly raising additional capital if needed.
Analyst Bruce Jackson focused on the Q4 cost structure, asking where gross margin and SG&A should settle after the quarter’s special charges. Leffler said gross margin should return to around 80% in Q4 and that SG&A should remain controlled aside from legal costs. Jackson also asked about reimbursement for the sBCC launch; George Jones said management believes there will be a clear path to reimbursement at launch, with Ameluz tubes reimbursed through the J code and procedure codes being finalized.
The call showed real commercial momentum: revenue, tube volume, orders, and new locations were all up year over year, and management said customer ordering had returned to prior-year levels after the ITC disruption. On top of that, the company now has an FDA-approved second indication, a filed third indication, and a cleared redesign of its lamp platform, which management says expands the addressable use of the existing sales force and installed base.
The balance sheet is still fragile, with only $3.2 million of cash, a $200,000 stockholders’ deficit, and explicit going-concern language. The company also remains exposed to legal and remediation costs from the ITC matter, and management said the appeals process timing and outcome are uncertain, while some recovery plans such as the working credit line and milestone payment are not fully within its control.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.5%
- Shares Outstanding
- 14.85M
- Float Shares
- 12.84M
of shares held by institutions
19 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 1.50M | ▲ 756.67K |
| Rosalind Advisors, Inc. | 1.28M | ▲ 111.65K |
| Renaissance Technologies LLC | 660.78K | ▲ 503.28K |
| Acadian Asset Management LLC | 164.30K | ▲ 164.30K |
| Jane Street Group, LLC | 116.38K | ▲ 23.38K |
| Vanguard Group Inc | 113.95K | 0 |
| Geode Capital Management, LLC | 110.51K | ▲ 33.82K |
| Citadel Advisors LLC | 104.94K | ▲ 104.94K |
| Vanguard Fiduciary Trust Co | 98.46K | ▲ 36.77K |
| Vanguard Capital Management LLC | 84.88K | ▲ 13.50K |
| Xtx Topco Ltd | 51.89K | ▲ 29.40K |
| Hrt Financial LP | 42.04K | ▼ 1.31K |
Held by 6 ETFs
Biggest fund positions in BFRI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 28, 26 | Luebbert Hermann | other | 62,500 |
| Jul 28, 26 | Luebbert Hermann | other | 62,500 |
| Jul 28, 26 | Leffler Eugene Frederick | other | 31,250 |
| Jul 28, 26 | Leffler Eugene Frederick | other | 31,250 |
| Mar 4, 26 | Weber Kevin Daniel | other | 20,000 |
| Mar 5, 26 | Luebbert Hermann | other | 137,500 |
| Mar 4, 26 | Luebbert Hermann | other | 125,000 |
| Mar 4, 26 | Luebbert Hermann | other | 125,000 |
| Mar 5, 26 | Luebbert Hermann | other | 137,500 |
| Mar 5, 26 | Leffler Eugene Frederick | other | 87,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BFRI coverage
Recent articles, reports, and earnings notes.
No research on BFRI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BFRI report →Biofrontera: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 17
Biofrontera Inc. (BFRI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
globenewswire.com · Nov 13
Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
globenewswire.com · Nov 6
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
globenewswire.com · Oct 8
Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast
defenseworld.net · Oct 5
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
globenewswire.com · Sep 14
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.